Sandoz to Acquire Genetic Therapy

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 8
Volume 4
Issue 8

BASLE, Switzerland--Sandoz Ltd. has entered into a merger agreement with Genetic Therapy, Inc (Gaithersburg, Md) with a cash tender offer valued at $295 million. The acquisition "puts Sandoz at the forefront of gene therapy technology," said Daniel Vasella, MD, CEO of Sandoz Pharma.

BASLE, Switzerland--Sandoz Ltd. has entered into a merger agreementwith Genetic Therapy, Inc (Gaithersburg, Md) with a cash tenderoffer valued at $295 million. The acquisition "puts Sandozat the forefront of gene therapy technology," said DanielVasella, MD, CEO of Sandoz Pharma.

In other news, Genetic Therapy announced the start of a gene therapytrial in multiple myeloma patients who have relapsed after allogeneicBMT. Investigators from the University of Arkansas and GeneticTherapy will perform an ex vivo transfer of the thymidine kinasegene into the original marrow donor's T cells, making these cellssusceptible to destruction by ganciclovir (Cytovene). These cellswill then be infused into the patient.

Because data indicate that a graft vs myeloma effect can precedegraft vs host disease (GVHD), 3 weeks after infusion of the donorT cells, ganci-clovir will be administered to destroy the T cellsthat cause GVHD. Patients who do not achieve a complete remissionwill receive another infusion of donor T cells, followed by ganciclovironly if significant GVHD develops.

Related Videos
A panel of 3 experts on multiple myeloma
A panel of 3 experts on multiple myeloma
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Aparna Parikh, MD, with the Oncology Brothers presenting slides
Tailoring neoadjuvant therapy regimens for patients with mismatch repair deficient gastroesophageal cancer represents a future step in terms of research.
Not much is currently known about the factors that may predict pathologic responses to neoadjuvant immunotherapy in this population, says Adrienne Bruce Shannon, MD.
The toxicity profile of tislelizumab also appears to look better compared with chemotherapy in metastatic esophageal squamous cell carcinoma.